Renouf, Daniel J <br/><br/>
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.  [electronic resource] 

 -  Investigational new drugs  Apr 2012 
 - 779-86 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-010-9611-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Benzodioxoles--administration & dosage<br/>Canada<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Pancreatic Neoplasms--drug therapy<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinazolines--administration & dosage<br/>Treatment Outcome<br/>Tumor Burden--drug effects<br/>src-Family Kinases--antagonists & inhibitors<br/>Gemcitabine